Abstract
Topical imiquimod is an immune response modifier FDA approved for the treatment of anogenital warts. Recent studies have reported its effectiveness in the treatment of some types of basal cell carcinomas. There have also been some case reports and case series reporting success treating of squamous cell carcinoma in situ with imiquimod. We report two patients with squamous cell carcinoma in situ and one with invasive squamous cell carcinoma treated with 5% imiquimod cream. Lesions were located on shin, posterior shoulder, and nasal tip. 5% imiquimod cream was applied at night for six weeks. Side effects included erythema and crusting in one patient. Biopsies taken four weeks after treatment revealed no residual squamous cell carcinoma in situ or squamous cell carcinoma. Topical 5% imiquimod cream is becoming established as a promising treatment for squamous cell carcinoma in situ. It also seems to be an alternative treatment for some cases of squamous cell carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 669-673 |
| Number of pages | 5 |
| Journal | Journal of drugs in dermatology : JDD |
| Volume | 2 |
| Issue number | 6 |
| State | Published - Jan 1 2003 |
Fingerprint
Cite this
Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma. / Nouri, Keyvan; O'Connell, Christopher; Rivas, Maria Patricia.
In: Journal of drugs in dermatology : JDD, Vol. 2, No. 6, 01.01.2003, p. 669-673.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma.
AU - Nouri, Keyvan
AU - O'Connell, Christopher
AU - Rivas, Maria Patricia
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Topical imiquimod is an immune response modifier FDA approved for the treatment of anogenital warts. Recent studies have reported its effectiveness in the treatment of some types of basal cell carcinomas. There have also been some case reports and case series reporting success treating of squamous cell carcinoma in situ with imiquimod. We report two patients with squamous cell carcinoma in situ and one with invasive squamous cell carcinoma treated with 5% imiquimod cream. Lesions were located on shin, posterior shoulder, and nasal tip. 5% imiquimod cream was applied at night for six weeks. Side effects included erythema and crusting in one patient. Biopsies taken four weeks after treatment revealed no residual squamous cell carcinoma in situ or squamous cell carcinoma. Topical 5% imiquimod cream is becoming established as a promising treatment for squamous cell carcinoma in situ. It also seems to be an alternative treatment for some cases of squamous cell carcinoma.
AB - Topical imiquimod is an immune response modifier FDA approved for the treatment of anogenital warts. Recent studies have reported its effectiveness in the treatment of some types of basal cell carcinomas. There have also been some case reports and case series reporting success treating of squamous cell carcinoma in situ with imiquimod. We report two patients with squamous cell carcinoma in situ and one with invasive squamous cell carcinoma treated with 5% imiquimod cream. Lesions were located on shin, posterior shoulder, and nasal tip. 5% imiquimod cream was applied at night for six weeks. Side effects included erythema and crusting in one patient. Biopsies taken four weeks after treatment revealed no residual squamous cell carcinoma in situ or squamous cell carcinoma. Topical 5% imiquimod cream is becoming established as a promising treatment for squamous cell carcinoma in situ. It also seems to be an alternative treatment for some cases of squamous cell carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=1342266717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1342266717&partnerID=8YFLogxK
M3 - Article
C2 - 14711149
AN - SCOPUS:1342266717
VL - 2
SP - 669
EP - 673
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
SN - 1545-9616
IS - 6
ER -